Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00042211 |
This study will evaluate the effectiveness of a Problem Solving Treatment in preventing depression in elderly patients with age-related macular degeneration (AMD).
Condition | Intervention | Phase |
---|---|---|
Depression Macular Degeneration |
Behavioral: Problem Solving Treatment Behavioral: Control |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Preventing Depression in Macular Degeneration |
Enrollment: | 206 |
Study Start Date: | February 2001 |
Study Completion Date: | January 2006 |
Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Problem Solving Treatment
|
Behavioral: Problem Solving Treatment
Brief Cognitive Behavioral Therapy
|
2: Active Comparator
Control
|
Behavioral: Control
No treatment control
|
AMD is the most common cause of blindness in older adults. The disease limits the ability to read, see familiar faces, and walk independently. Almost 2 million persons (about 5 percent of the U.S. population over age 65) are now affected, and this number will triple by the year 2020. This study will target patients with neovascular AMD (NV-AMD), a form of AMD which can lead to sudden vision loss, substantial disability, and depression. Because depression is itself disabling and not likely to be recognized nor treated by ophthalmologists, preventing depression in people with NV-AMD is important.
Patients are randomly assigned to either PST or a usual care control condition. The primary outcome measure is a DSM-IV diagnosis of depression. Patients are evaluated at baseline, Month 2 (immediately post-intervention), Month 6 (for the primary efficacy analysis), and Month 12 (to evaluate sustained effects). The study will also assess the impact of PST on levels of disability and vision-related quality of life.
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Responsible Party: | Thomas Jefferson University ( Barry Rovner, MD ) |
Study ID Numbers: | R01 MH61331, DATR A4-GPS |
Study First Received: | July 24, 2002 |
Last Updated: | February 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00042211 |
Health Authority: | United States: Federal Government |
Depressive Disorder Blindness Aged |
Depression Mental Disorders Eye Diseases Mood Disorders Retinal Degeneration Macular Degeneration |
Blindness Depressive Disorder Retinal Diseases Retinal degeneration Behavioral Symptoms |